Shopping Cart 0
Cart Subtotal
USD 0

OpGen Inc (OPGN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

OpGen Inc (OpGen) is a molecular diagnostics company that harnesses genomic analysis and bioinformatics to prevent the threat of antibiotic resistance and multi drug resistant organisms (MDROs). The company's clinical laboratory services include high resolution microbial sequence analysis, swift detection and analysis of antibiotic resistance, and detection of pathogens in blood cultures. OpGen's develops products that includes QuickFISH, and PNA FISH products, Acuitas products, and Acuitas Lighthouse informatics. OpGen offers its surveillance products and customized screening services to healthcare providers to protect the hospital biome and optimize patient care. The company sells its products in the US and abroad. OpGen is headquartered in Gaithersburg, Maryland, the US.

OpGen Inc (OPGN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

OpGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

OpGen Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

OpGen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

OpGen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

OpGen Inc, Medical Devices Deals, 2012 to YTD 2018 10

OpGen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

OpGen Inc, Pharmaceuticals & Healthcare, Deal Details 12

Venture Financing 12

OpGen Raises USD1.2 Million in Venture Financing 12

Opgen Raises USD1 Million in Venture Financing 13

AdvanDx Raises USD 12 Million In Series B-1 Venture Financing 14

OpGen Raises USD 2 Million In Venture Financing 15

OpGen Raises Additional USD 2.6 Million In Series C Financing 16

OpGen Raises Additional USD1.4 Million in Venture Financing 18

Partnerships 19

OpGen and Hitachi High-Technologies Amends its Agreement to Develop Human Chromosome Mapping Service 19

OpGen Enters Into Agreement With Applied Maths To Develop Whole Genome Mapping Software 20

OpGen Enters Into Agreement With UC Davis To Develop Microbial Reference Genomes 21

Life Technologies Enters Into Co-Development Agreement With OpGen 22

OpGen Enters Into Co-Development Agreement With In-Q-Tel 23

Equity Offering 24

OpGen Raises USD12 Million in Public Offering of Units 24

OpGen Raises USD0.1 Million in Equity Offering 26

Opgen Raises USD10 Million in Public Offering of Units 27

OpGen Raises USD5 Million in Private Placement of Shares 28

OpGen Raises USD17 Million in IPO 29

Debt Offering 31

OpGen Raises USD0.5 Million in Debt Financing 31

OpGen Raises USD1.5 Million in Private Placement of 8% Notes 32

OpGen Inc-Key Competitors 33

OpGen Inc-Key Employees 34

OpGen Inc-Locations And Subsidiaries 35

Head Office 35

Other Locations & Subsidiaries 35

Recent Developments 36

Financial Announcements 36

Oct 15, 2018: OpGen provides business and preliminary financial update 36

Aug 02, 2018: Opgen announces second quarter 2018 financial results 37

May 08, 2018: OpGen Announces First Quarter 2018 Financial Results 39

Mar 15, 2018: OpGen Announces Fourth Quarter and Full Year 2017 Financial Results 41

Aug 08, 2017: OpGen Reports 2017 Second Quarter Financial Results and Provides Business Update 43

Apr 26, 2017: OpGen Announces 2017 First Quarter Financial Results 45

Mar 23, 2017: OpGen Announces 2016 Fourth Quarter and Year End Financial Results 46

Jan 26, 2017: OpGen Reports Preliminary Fourth Quarter and Full Year 2016 Financial Results 47

Corporate Communications 49

Feb 05, 2018: OpGen Regains Compliance With Nasdaq Listing Requirements 49

Apr 27, 2017: OpGen Appoints Tina S. Nova, Ph.D. to Board of Directors 50

Product News 51

Feb 01, 2018: OpGen Introduces New RUO Rapid Test for Infection Control and Surveillance Studies 51

Appendix 52

Methodology 52

About GlobalData 52

Contact Us 52

Disclaimer 52


List Of Figure

List of Figures

OpGen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

OpGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

OpGen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

OpGen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

OpGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

OpGen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

OpGen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

OpGen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

OpGen Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

OpGen Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

OpGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

OpGen Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

OpGen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

OpGen Inc, Deals By Therapy Area, 2012 to YTD 2018 9

OpGen Inc, Medical Devices Deals, 2012 to YTD 2018 10

OpGen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

OpGen Raises USD1.2 Million in Venture Financing 12

Opgen Raises USD1 Million in Venture Financing 13

AdvanDx Raises USD 12 Million In Series B-1 Venture Financing 14

OpGen Raises USD 2 Million In Venture Financing 15

OpGen Raises Additional USD 2.6 Million In Series C Financing 16

OpGen Raises Additional USD1.4 Million in Venture Financing 18

OpGen and Hitachi High-Technologies Amends its Agreement to Develop Human Chromosome Mapping Service 19

OpGen Enters Into Agreement With Applied Maths To Develop Whole Genome Mapping Software 20

OpGen Enters Into Agreement With UC Davis To Develop Microbial Reference Genomes 21

Life Technologies Enters Into Co-Development Agreement With OpGen 22

OpGen Enters Into Co-Development Agreement With In-Q-Tel 23

OpGen Raises USD12 Million in Public Offering of Units 24

OpGen Raises USD0.1 Million in Equity Offering 26

Opgen Raises USD10 Million in Public Offering of Units 27

OpGen Raises USD5 Million in Private Placement of Shares 28

OpGen Raises USD17 Million in IPO 29

OpGen Raises USD0.5 Million in Debt Financing 31

OpGen Raises USD1.5 Million in Private Placement of 8% Notes 32

OpGen Inc, Key Competitors 33

OpGen Inc, Key Employees 34

OpGen Inc, Subsidiaries 35

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

OpGen Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.